SUNRISE, Fla., May 11, 2026
Transpire Bio Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s abbreviated new drug application (ANDA) for a generic version of the high-strength Trelegy® Ellipta® inhalation powder, marking a significant milestone in the development of affordable respiratory therapies for asthma and chronic obstructive pulmonary disease (COPD) patients in the United States. The filing covers the high-strength formulation containing fluticasone furoate, umeclidinium, and vilanterol inhalation powder (200 mcg/62.5 mcg/25 mcg), a widely prescribed triple-combination respiratory treatment currently marketed by GSK.
Potential First-to-File Advantage Strengthens Transpire Bio’s Generic Franchise
According to public FDA records, Transpire Bio believes it is the first company to submit an ANDA with a Paragraph IV certification for the high-strength Trelegy® Ellipta® product under the Hatch-Waxman Act. If approved, the company may qualify for 180 days of generic market exclusivity, potentially providing a major commercial opportunity in the rapidly growing respiratory therapeutics market. The development highlights the company’s increasing presence in the complex generic drug-device combination products sector, an area that requires extensive formulation, inhalation delivery, and regulatory expertise.
Trelegy® Ellipta® remains one of the most commercially successful respiratory therapies in the U.S., generating approximately $8 billion in annual U.S. sales during 2025, according to IQVIA data. The product is approved for the maintenance treatment of adult asthma patients and individuals suffering from COPD, conditions that continue to affect millions globally. A substitutable generic alternative could significantly improve patient access and affordability while increasing market competition within the respiratory drug category.
Respiratory Innovation and Advanced Inhalation Technology Drive Growth
Advertisement
Dr. Xian-Ming Zeng, Chief Executive Officer of Transpire Bio, stated that the FDA acceptance demonstrates the company’s ability to advance highly complex generic programs while simultaneously expanding its innovative inhalation medicine pipeline. The company noted that this filing may represent its third potential first-to-file ANDA submission, following earlier generic development programs for Breo® and Trelegy® inhalation therapies.
Transpire Bio emphasized that its South Florida-based scientific and manufacturing teams continue to strengthen the company’s integrated respiratory development platform. Chief Scientific Officer Dr. Abhishek Gupta highlighted the organization’s expertise in drug-device combination development, advanced inhalation formulations, and scalable manufacturing capabilities. The company operates state-of-the-art facilities dedicated to inhaled therapeutics manufacturing and development in the United States.
Expanding Pipeline Targets Pulmonary and Systemic Diseases
Beyond its generic respiratory portfolio, Transpire Bio is actively building a pipeline of innovative inhalation-based medicines targeting both pulmonary and systemic diseases. The company currently has multiple investigational assets under development for Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF), two severe lung diseases with significant unmet medical needs. Additional pipeline programs focus on Pulmonary Arterial Hypertension (PAH), Diabetes, Obesity, Parkinson’s Disease Psychosis, and Glioblastoma.
The company’s proprietary inhalation technology platforms include dry-powder inhalers and soft mist inhalers, supporting the delivery of complex therapeutics through advanced respiratory drug administration systems. Industry analysts continue to view inhalation-based therapies as an expanding segment within pharmaceutical innovation due to their ability to enhance targeted drug delivery and patient compliance.
The FDA filing acceptance further positions Transpire Bio as an emerging player within the respiratory therapeutics and complex generics landscape while reinforcing broader industry trends focused on affordable access, advanced inhalation technologies, and next-generation pulmonary treatments.
Source: Transpire Bio press release
